Common Warts Market
DelveInsight’s ‘Common Warts–Market Insights, Epidemiology, and Market Forecast—2032’ report deliver an in-depth understanding of the Common Warts, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Common Warts market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Common Warts symptoms market size from 2019 to 2032 segmented by seven major markets. The report also covers current Common Warts symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Geographies Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2019–2032
Common Warts Disease Understanding and Treatment Algorithm
Common Warts Overview
Common warts, also known as verruca vulgaris, are caused by nonmalignant strains of human papillomavirus (HPV). They are typically benign lesions that rarely have malignant transformation. On the skin, they appear as rough, painless papules that can be grey or flesh-colored and are found on different body areas. Other subtypes of HPV that are associated with cervical cancer are not the same strains that cause verruca vulgaris (Pope et al., 2020).
Warts are noncancerous (benign) skin growths, which come in various forms and are contagious and very common: Most people will have one at some point in their lives. Although they can affect people at any age, warts are most common among children and teenagers.
Most warts are harmless and will go away on their own within a few weeks or months. But they can be bothersome and unattractive, and some people feel ashamed. There are several different treatments that can make warts go away more quickly – but they do not always work.
Viral warts are not the same as “senile warts” (seborrheic keratosis), which usually first appear in older age and are not contagious. Senile warts are also quite harmless but permanent (Institute for Quality and Efficiency in Health Care [IQWiG], 2019).
Common warts are easy to distinguish from other types of warts, such as genital, filiform, and plantar warts. They are most commonly found on the hands or fingers, though they can also be found on the knees, ankles, arms, and legs.
There are over 100 subtypes of the HPV virus, but only a few types can cause skin warts at selective anatomical sites. However, with skin contact, the HPV can be transferred to any body part. HPV tends to cause genital warts, flat warts, and palmoplantar warts. Warts are easily transmitted by direct or indirect contact, especially if the normal epithelial barrier is disrupted. Besides the skin, warts can also occur on mucous membranes. In general, HPV usually only infects the epithelial layers of the skin, and systemic dissemination is very rare. The virus is known to replicate in the upper level of the epithelium, but the virus particles also can be found in the basal layer.
Common warts are associated with HPV types 2, 4 (most common), followed by types 1, 3, 27, 29, and 57 (Aboud & Nigam, 2021).
Humans are affected by many forms of warts, also known as verruca. Among them are common warts, flat warts, plantar warts, filiform warts, periungual warts, mosaic warts, and genital warts. Each variety of warts has distinguishing traits that set it apart from the others.
Common warts are found to be preferentially associated with HPV2. The small endophytic keratosis puncta-like variety may also be induced by HPV4 and the hyperproliferative papillomatous variety by HPV7.
The diagnosis of verruca vulgaris can be made after a small piece of the growth is removed in a procedure called a biopsy or after the entire growth is removed in a procedure called an excision. The tissue is then sent to a pathologist who examines it under the microscope.
Common Warts Diagnosis and Treatment
It covers the details of conventional and current medical therapies and diagnosis available in the Common Warts market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.
The DelveInsight Common Warts market report gives a thorough understanding of Common Warts symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides Common Warts treatment algorithms and treatment guidelines in the US, Europe, and Japan.
Common Warts Epidemiology
The epidemiology division’s Common Warts symptoms provide insights about the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Common Warts epidemiology segmented as the Diagnosed Prevalent Cases of Common Warts, Gender specific Prevalence of Common Warts. The report includes the prevalent Common Warts scenario in 7MM, covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
Country Wise- Common Warts Epidemiology
The epidemiology segment also provides the Common Warts epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total 7MM prevalent cases of Common Warts were 14,900,229 in 2020.
Common Warts Drug Chapters
The drug chapter segment of the Common Warts report encloses the detailed analysis of Common Warts marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Common Warts clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Products detail in the report…
Common Warts Emerging Drugs
Candin: Nielsen BioSciences
Results in Phase II research involving common and non-common warts among adults were highly encouraging and are now advancing clinical research into the use of the antigen in common and non-common warts. Though not treated, plantar, periungual, flat, facial, and genital warts were evaluated in the Phase II subjects (Nielsen Biosciences, 2021).
Treatment of common warts with intralesional candida antigen appears safe and effective. Further studies are warranted to confirm the dosing scheme and demonstrate safety and effectiveness for FDA licensure (Smith & Johnson, 2019).
VP-102: Verrica Pharmaceutical
The pharmacodynamic action of the active ingredient in VP-102 (cantharidin) is a vesicant. VP-102 is currently under the US FDA review and could potentially be the first product approved by the FDA to treat molluscum contagiosum (molluscum) – a common, highly contagious skin disease that affects an estimated 6 million people in the United States, primarily children. If approved, VP-102 will be marketed in the United States under the conditionally accepted brand name, YCANTH. Verrica has announced positive top-line results from its COVE-1 Phase II open-label clinical study of VP-102 to treat common warts (Verrica Pharmaceuticals., 2021).
Products detail in the report…
Common Warts Market Outlook
The Common Warts market outlook of the report helps build a detailed comprehension of the historic, current, and forecasted Common Warts market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.
This segment gives a thorough detail of Common Warts market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, Common Warts market in 7MM is expected to change in the study period 2019–2032.
Key Findings
This section includes a glimpse of the Common Warts market in 7MM. The market size of Common Warts in the seven major markets was found to be USD 720.03 million in 2020.
The United States Market Outlook
This section provides a total of Common Warts market size and market size by therapies in the United States.
The United States accounts for the highest Common Warts market size compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
EU-5 Countries: Market Outlook
The total Common Warts market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Japan Market Outlook
The total Common Warts market size and market size by therapies in Japan are also mentioned.
Common Warts Drugs Uptake
This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2019–2032. The analysis covers Common Warts market uptake by drugs, patient uptake by therapies, and drug sales.
This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again be useful in investigating factors important in the market uptake in making financial and regulatory decisions.
Common Warts Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Common Warts key players involved in developing targeted therapeutics.
Major players Candin (Nielsen BioSciences), VBP-245: Veloce BioPharma, VP-102: Verrica Pharmaceutical etc being assessed as potential therapies to be available in the market in the coming future.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Common Warts emerging therapies.
KOL Views
To keep up with current market trends, we take KOLs and SME’s opinion working Common Warts domain through primary research to fill the data gaps and validate our secondary research. Their opinions help understand and validate current and emerging therapies treatment patterns or Common Warts market trends. This will support the clients in potential upcoming novel treatment by identifying the market’s overall scenario and the unmet needs.
Competitive Intelligence Analysis
We perform a Competitive and Market Intelligence analysis of the Common Warts Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
- The report covers the descriptive overview of Common Warts explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
- Comprehensive insight has been provided into the Common Warts epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Common Warts is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of Common Warts market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies by understanding trends shaping and driving the global Common Warts market
Report Highlights
- In the coming years, Common Warts market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The companies and academics are working to assess challenges and seek opportunities that could influence Common Warts R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing therapies for Common Warts. The launch of emerging therapies will significantly impact the Common Warts market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Common Warts
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Common Warts Report Insights
- Patient Population
- Therapeutic Approaches
- Common Warts Pipeline Analysis
- Common Warts Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Common Warts Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- Common Warts Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Common Warts Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
Key Questions
Market Insights:
- What was the Common Warts Market share (%) distribution in 2019, and how would it look in 2032?
- What would be the Common Warts total market Size as well as market Size by therapies across the 7MM during the forecast period (2019–2032)?
- What are the market’s key findings across 7MM, and which country will have the largest Common Warts market Size during the forecast period (2019–2032)?
- At what CAGR, the Common Warts market is expected to grow by 7MM during the forecast period (2019–2032)?
- What would be the Common Warts market outlook across the 7MM during the forecast period (2019–2032)?
- What would be the Common Warts market growth till 2032, and what will be the resultant market Size in the year 2032?
- How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
- What are the disease risk, burden, and unmet needs of Common Warts?
- What is the historical Common Warts patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What would be the forecasted patient pool of Common Warts in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What will be the growth opportunities in the 7MM concerning the patient population about Common Warts?
- Out of all 7MM countries, which country would have the highest prevalent Common Warts population during the forecast period (2019–2032)?
- At what CAGR is the population expected to grow by 7MM during the forecast period (2019–2032)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
- What are the current options for the treatment of Common Warts?
- What are the current treatment guidelines for treating Common Warts in the USA, Europe, and Japan?
- What are the Common Warts marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
- How many companies are developing therapies for the treatment of Common Warts?
- How many therapies are developed by each company for the treatment of Common Warts?
- How many emerging therapies are in the mid-stage and late development stages to treat Common Warts?
- What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Common Warts therapies?
- What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Common Warts and their status?
- What are the key designations that have been granted for the emerging therapies for Common Warts?
- What are the global historical and forecasted markets of Common Warts?
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving the Common Warts market
- To understand the future market competition in the Common Warts market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Common Warts in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for Common Warts market
- To understand the future market competition in the Common Warts market
1. Key Insights
2. Report Introduction
3. Common Warts Market Overview at a Glance
3.1. Market Share (%) Distribution of Common Warts in 2019
3.2. Market Share (%) Distribution of Common Warts in 2032
4. Executive Summary of Common Warts
5. Disease Background and Overview
5.1. Introduction
5.2. Signs and Symptoms
5.3. Etiology
5.4. Classification
5.5. Risk Factors
5.6. Histopathology
5.7. Pathophysiology
5.8. Diagnosis
5.9. Differential diagnosis of verruca vulgaris pathology
6. Management and Treatment
6.1. Diagnostic and Treatment Guidelines
6.1.1. British Association of Dermatologists’ guidelines for the management of cutaneous warts 2014
7. Epidemiology and Patient Population
7.1. Key Findings
7.2. 7MM Total Prevalent Patient Population of Common Warts
7.3. Assumptions and Rationales
7.4. The United States
7.4.1. Diagnosed prevalent cases of Common warts in the United States
7.4.2. Gender specific Prevalence of Common Warts in the United States
7.5. EU-5
7.5.1. Diagnosed Prevalent Cases of Common Warts in EU-5
7.5.2. Gender specific Prevalence of Common Warts in EU-5
7.6. Japan
7.6.1. Diagnosed Prevalent cases of Common warts in Japan
7.6.2. Gender specific Prevalence of Common Warts in Japan
8. Patient Journey 1
9. Patient Journey 2
10. Emerging Therapies
10.1. Candin: Nielsen BioSciences
10.1.1. Drug Description
10.1.2. Product Development
10.1.3. Clinical Development
10.1.4. Safety and Efficacy
10.1.5. Clinical Trials Information
10.1.6. Product Profile
10.2. VBP-245: Veloce BioPharma
10.2.1. Drug Description
10.2.2. Clinical Development
10.2.3. Safety and Efficacy
10.2.4. Clinical Trials Information
10.2.5. Product Profile
10.3. VP-102: Verrica Pharmaceutical
10.3.1. Drug Description
10.3.2. Product Development
10.3.3. Clinical Development
10.3.4. Safety and Efficacy
10.3.5. Clinical Trials Information
10.3.6. Product Profile
10.4. CLS006: Maruho Co., Ltd.
10.4.1. Product Description 63
10.4.2. Other Developmental Activities
10.4.3. Clinical Development 63
10.4.4. Clinical Trials Information
10.4.5. Product Profile
10.5. A-101: Aclaris Therapeutics, Inc.
10.5.4. Product Description
10.5.2. Clinical Development 65
10.5.3. Clinical Trials Information 65
10.5.4. Product Profile
11. Current Marketed Therapies: Generics
11.1. Salicylic acid
11.2. Bleomycin
11.3. 5-Fluorouracil
11.4. Cimetidine
11.5. Imiquimod
12. Other Topical Agents
12.1. Cantharidin
12.2. Retinoids
12.3. Zinc
13. Common Warts: 7 Major Market Analysis
13.1. Key Findings
13.2. Market Size of Common Warts in 7MM
13.3. Market Size of Common Warts by Therapies
14. Market Outlook
14.1. United States Market Size
14.1.1. Total Market Size of Common warts in the United States
14.1.2. Market Size of Common Warts by Therapies in United States
14.2. EU-5 Market Size
14.2.1. Total Market Size of Common warts in EU-5
14.2.2. Market Size of Common Warts by Therapies in EU-5
14.3. Japan
14.3.1. Total Market size of Common Warts in Japan
14.3.2. Market Size of Common Warts by Therapies in Japan
15. KOL Views
16. Unmet Needs
17. SWOT Analysis
18. Appendix
18.1. Bibliography
18.2. Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
List of Table
Table 1: Summary of Common Warts, Market, Epidemiology, and Key Events (2019–2032)
Table 2: Total Prevalent Patient Population of Common Warts in 7MM (2019–2032)
Table 3: Diagnosed Prevalent cases of Common warts in the United States (2019–2032)
Table 4: Gender specific Prevalence of Common Warts in the United States (2019–2032)
Table 5: Diagnosed Prevalent cases of Common warts in EU-5 (2019–2032)
Table 6: Gender specific Prevalence of Common Warts in EU-5 (2019–2032)
Table 7: Diagnosed Prevalent cases of Common warts in Japan (2019–2032)
Table 8: Gender specific Prevalence of Common Warts in Japan (2019–2032)
Table 9: Candin, Clinical Trial Description, 2021
Table 10: VBP-245, Clinical Trial Description, 2021
Table 11: VP-102, Clinical Trial Description, 2021
Table 12: CLS006, Clinical Trial Description, 2021
Table 13: A-101, Clinical Trial Description, 2021
Table 14: 7 Major Market Size of Common Warts in USD Million (2019–2032)
Table 15: 7 Major Market Size of Common Warts by Therapies in USD Million (2019–2032)
Table 16: United States Market Size of Common warts in USD Million (2019–2032)
Table 17: United States Market Size of Common warts by Therapies in USD Million (2019–2032)
Table 18: EU-5 Market Size of Common warts in USD Million (2019–2032)
Table 19: The EU-5 Market Size of Common Warts by Therapies in USD Million (2019–2032)
Table 20: Japan Market Size of Common Warts in USD Million (2019–2032)
Table 21: Japan Market Size of Common Warts by Therapies in USD Million (2018–2030)
List of Figures
Figure 1: Illustration of a wart on the thumb
Figure 2: Classification of Warts
Figure 3: Verruca vulgaris pathology
Figure 4: Diagnosed Prevalent Population of Common Warts in the 7MM (2019–2032)
Figure 5: Diagnosed Prevalent cases of Common Warts in the United States (2019–2032)
Figure 6: Gender specific Prevalence of Common Warts in the United States (2019–2032)
Figure 7: Diagnosed Prevalent cases of Common Warts in the United States (2019–2032)
Figure 8: Gender specific Prevalence of Common Warts in EU-5 (2019–2032)
Figure 9: Diagnosed Prevalent cases of Common warts in Japan (2019–2032)
Figure 10: Gender specific Prevalence of Common Warts in Japan (2019–2032)
Figure 11: 7 Major Market Size of Common Warts in USD Million (2018–2030)
Figure 12: 7 Major Market Size of Common Warts by Therapies in USD Million (2019–2032)
Figure 13: Total Market Size of Common warts in the United States, USD Million (2019–2032)
Figure 14: The United States Market Size of Common warts by Therapies in USD Million (2019–2032)
Figure 15: Total Market Size of Common Warts in EU-5, USD Million (2019–2032)
Figure 16: The EU-5 Market Size of Common Warts by Therapies in USD Million (2019–2032)
Figure 17: Market Size of Common Warts in Japan, USD Million (2019–2032)
Figure 18: The Japan Market Size of Common Warts by Therapies in USD Million (2019–2032)
Nielsen BioSciences
Veloce BioPharma
Verrica Pharmaceutical
Maruho Co., Ltd
Aclaris Therapeutics, Inc.